Form 4: Aquestive Therapeutics Executive Stock Withholding

Chief People Officer Peter E. Boyd reported the withholding of 56,778 shares to satisfy tax obligations related to PSU vesting.

Summary

• Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, Inc., executed a transaction involving the withholding of 56,778 shares of common stock.
• The transaction occurred on May 5, 2026, at a price of $4.18 per share.
• The withholding was conducted to satisfy tax obligations associated with the vesting of Performance Stock Units (PSUs).
• Following this transaction, the reporting person maintains a direct beneficial ownership of 281,731 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as it represents routine tax compliance rather than a discretionary sale of stock.

Positives

• The transaction reflects the vesting of performance-based equity, indicating the achievement of pre-defined corporate or individual performance milestones.

Negatives

• The transaction resulted in a reduction of the executive's direct shareholding in the company.

Risks

• None identified; this is a routine administrative transaction related to tax obligations.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a standard regulatory filing for executive compensation management and does not signal a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The practice of withholding shares to satisfy tax obligations upon the vesting of equity awards is a standard industry practice for publicly traded companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related equity adjustment.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Form 4, Insider Transaction, Equity Vesting, Tax Withholding